A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes

The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CLint, in vivo) and hepatic clearance (CLh) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fu(b)) and in vitro incubations (fu(inc)). Human CLint, in vivo was projected using in vitro data together with biological scaling factors and compared with the unbound intrinsic clearance (CLint, ub, in vivo) estimated from clinical data using liver models with and without the various fu terms. For incubations conducted with fetal calf serum (n = 14), the observed CLint, in vivo was modeled well assuming fu(inc) and fu(b) were equivalent. CL(int, ub, in viv)o was predicted best using both fu(b) and fu(inc) for other hepatocyte data (n = 56; r(2) = 0.78, p = 3.3 x 10(-19), average fold error = 5.2). A similar model for CLint, ub, in vivo was established for microsomal data (n = 37; r(2) = 0.77, p = 1.2 x 10(-12), average fold error = 6.1). Using the model for CLint, ub, in vivo (including a further empirical scaling factor), the CLh in humans was also calculated according to the well stirred liver model for the most extensive dataset. CLint, in vivo and CLh were both predicted well using in vitro human data from several laboratories for acidic, basic, and neutral drugs. The direct use of this model using only in vitro human data to predict the metabolic component of CLh is attractive, as it does not require extra information from preclinical studies in animals.